Cannenta is a biotechnology venture developing advanced wound care products. The company has a unique angiogenic factor which can be incorporated in a range of dressing products to accelerate vascularisation in wound beds and thus provide a foundation for effective wound recovery. The technology can be applied to a range of products and indications including treatment of diabetic foot ulcers and other chronic wounds. Cannenta is working with established manufacturers to incorporate the technology into suitable product carriers and intends to distribute to a global market following a clinical development program.